Hirudin In Renal Insufficiency

Karl-Georg Fischer

doi:10.1055/s-2002-35288

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2002; 28(5): 467-482
DOI: 10.1055/s-2002-35288

Hirudin In Renal Insufficiency

Karl-Georg Fischer

University Hospital Freiburg, Department of Medicine, Division of Nephrology and General Medicine, Freiburg, Germany

Abstract

ABSTRACT

Recombinant hirudins (r-hirudins) are potent direct thrombin inhibitors increasingly used for alternative anticoagulation, especially in heparin-induced thrombocytopenia. R-hirudins are almost exclusively eliminated by the kidneys, and a close correlation between r-hirudin clearance and endogenous creatinine clearance has been observed. Accordingly, the pharmacokinetics of r-hirudin are altered in patients with renal insufficiency. A decline of renal r-hirudin clearance is associated with an increase of r-hirudin half-life and the area under the curve (AUC). Therefore, renal impairment necessitates reduction of r-hirudin dose to avoid overdose or inadequate accumulation of the thrombin inhibitor. To this end, close monitoring of r-hirudin anticoagulation is required, which at best is performed by measuring r-hirudin blood levels by ecarin clotting times (ECT) or chromogenic assays, in addition to activated partial thromboplastin time (aPTT). Recent studies showed that r-hirudin anticoagulation is feasible in acute or chronic renal failure treated with continuous or intermittent renal replacement therapy, if appropriate r-hirudin dosing and adequate monitoring are warranted. High-volume hemofiltration with r-hirudin-permeable hemodialyzers constitutes a valuable means to markedly reduce r-hirudin blood concentration and total r-hirudin body content in case of r-hirudin overdose or r-hirudin-associated bleeding. In the future, the hepatically eliminated direct thrombin inhibitor argatroban may facilitate alternative anticoagulation in patients with renal insufficiency.

KEYWORDS

Recombinant hirudin - renal insufficiency - pharmacokinetics - hemodialysis - dosing

Full Text

References

REFERENCES

1 Haycraft J B. Über die Einwirkung eines Sekretes des officinellen Blutegels auf die Gerinnbarkeit des Bluts. Naunyn Schmiedeberg Arch Exp Pathol Pharmakol . 1884; 18 209-217
2 Haas G. Über Versuche der Blutauswaschung am Lebenden mit Hilfe der Dialyse. Klin Wochenschr . 1925; 4 13-14
3 Adkins J C, Wilde M I. Lepirudin. A review of its potential place in the management of thrombotic disorders. BioDrugs . 1998; 10 227-255
4 Matheson A J, Goa K L. Desirudin. A review of its use in the management of thrombotic disorders. Drugs . 2000; 60 679-700
5 Nowak G. Pharmakologie der Hirudine und Hirudin-derivate [in German]. In: Greinacher A, ed. Hirudin in der vaskulären Medizin Bremen: Uni-Med 2001: 20-27
6 Markwardt F. Past, present and future of hirudin. Haemostasis . 1991; 21 11-26
7 Weitz J I, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invert . 1990; 86 385-391
8 Marbet G A, Verstraete M, Kienast J. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers. J Cardiovasc Pharmacol . 1993; 22 364-372
9 Hoechst Marion Roussel. Refludan-lepirudin: Scientific Monograph. 1997
10 Levèvre G, Duval M, Gauron S. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin. Clin Pharmacol Ther . 1997; 62 50-59
11 Bucha E, Nowak G, Czerwinski R, Thieler H. R-hirudin as anticoagulant in regular hemodialysis therapy: finding of therapeutic r-hirudin blood/plasma concentrations and respective dosages. Clin Appl Thromb Hemost . 1999; 5 164-170
12 Bichler J, Baynes J W, Thorpe S R. Catabolism of hirudin and thrombin-hirudin complexes in the rat. Biochem J . 1993; 296 771-776
13 Greinacher A. Recombinant hirudin for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia, 2nd ed New York: Dekker 2001: 349-380
14 Nowak G, Bucha E, Gööck T h, Thieler H, Markwardt F. Pharmacology of r-hirudin in renal impairment. Thromb Res . 1992; 66 707-715
15 Meyer B H, Luus H G, Müller F O, Badenhorst P N, Röthig H-J. The pharmacology of recombinant hirudin, a new anticoagulant. S Afr Med J . 1990; 78 268-270
16 Vanholder R C, Camez A, Veys N. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. Thromb Haemost . 1997; 77 650-655
17 Cockroft D W, Gault M H. Prediction of creatinine clearance from serum creatinine. Nephron . 1976; 16 31-34
18 Lindeman R D, Tobin J, Shock N W. Association between blood pressure and the rate of decline in renal function with age. Kidney Int . 1984; 26 861-868
19 Antman E M. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation . 1994; 90 1624-1630
20 Nurmohamed M T, Berckmans R J, Morriën-Salomons W M. Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment. Thromb Haemost . 1994; 72 685-692
21 Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost . 1996; 22 197-202
22 Hafner G, Roser M, Nauck M S. Methods for the monitoring of direct thrombin inhibitors. Semin Thromb Hemost . 2002; 28 425-430
23 Nowak G. Clinical monitoring of hirudin and direct thrombin inhibitors. Semin Thromb Hemost . 2001; 27 537-542
24 Zoldhelyi P, Webster M W, Fuster V. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters. Circulation . 1993; 88 2015-2022
25 Koster A, Pasic M, Bauer M, Kuppe H, Hetzer R. Hirudin as anticoagulant for cardiopulmonary bypass: importance of preoperative renal function. Ann Thorac Surg . 2000; 69 37-41
26 Iglesias J, Lieberthal W. Clinical evaluation of acute renal failure. In: Johnson RJ, Feehally J, eds. Comprehensive Clinical Nephrology }New York: Mosby 2000 15: 1-15.16
27 Woolfson R G, Hillman K. Causes of acute renal failure. In: Johnson RJ, Feehally J, eds. Comprehensive Clinical Nephrology New York: Mosby 2000 : 16.1-16.16
28 Warkentin T E, Levine M N, Hirsh J. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med . 1995; 332 1330-1335
29 Warkentin T E. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia, 2nd ed New York: Dekker 2001: 43-86
30 Fischer K G, van de Loo A, Böhler J. Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int . 1999; 56(Suppl 72) S46-S50
31 Kern H, Ziemer S, Kox W J. Bleeding after intermittent or continuous r-hirudin during CVVH. Intensive Care Med . 1999; 25 1311-1314
32 Vargas H O, von Heymann C, Lipps M. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Med . 2001; 27 673-679
33 Agnelli G, Renga C, Weitz J I, Nenci G G, Hirsh J. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin. Blood . 1992; 80 960-965
34 Schneider T, Heuer B, Deller A, Boesken W H. Continuous haemofiltration with r-hirudin (lepirudin) as anticoagulant in a patient with heparin induced thrombocytopenia (HIT II). Wien Klin Wochenschr . 2000; 112 552-555
35 Saner F, Hertl M, Broelsch C E. Anticoagulation with hirudin for continuous veno-venous hemodialysis in liver transplantation. Acta Anaesthesiol Scand . 2001; 45 914-918
36 Wittkowsky A K, Kondo L M. Lepirudin dosing in dialysis-dependent renal failure. Pharmacotherapy . 2000; 20 1123-1128
37 Winearls C G. Clinical evaluation and manifestations of chronic renal failure. In: Johnson RJ, Feehally, eds. Comprehensive Clinical Nephrology New York: Mosby 2000 68: 1-68.14
38 Vanholder R C, Camez A A, Veys N M. Recombinant hirudin: a specific thrombin inhibiting anticoagulant for hemodialysis. Kidney Int . 1994; 45 1754-1759
39 Van Wyk V, Badenhorst P N, Luus H G, Kotzé H F. A comparison between the use of recombinant hirudin and heparin during hemodialysis. Kidney Int . 1995; 48 1338-1343
40 Nowak G, Bucha E, Brauns I, Czerwinski R. Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long term application of r-hirudin in a haemodialysis patient. Wien Klin Wochenschr . 1997; 109 354-358
41 Dager W E, White R H. Use of lepirudin in patients with heparin-induced thrombocytopenia and renal failure requiring hemodialysis. Ann Pharmacother . 2001; 35 885-890
42 Müller A, Huhle G, Nowack R. Serious bleeding in a haemodialysis patient treated with recombinant hirudin. Nephrol Dial Transplant . 1999; 14 2482-2483
43 Steuer S, Boogen C, Plum J. Anticoagulation with r-hirudin in a patient with acute renal failure and heparin-induced thrombocytopenia. Nephrol Dial Transplant . 1999; 14(Suppl 4) 45-47
44 Bucha E, Kreml R, Nowak G. In vitro study of r-hirudin permeability through membranes of different haemodialyzers. Nephrol Dial Transplant . 1999; 14 2922-2926
45 Frank R D, Farber H, Stefanidis I, Lanzmich R, Kierdorf H P. Hirudin elimination by hemofiltration: a comparative in vitro study of different membranes. Kidney Int . 1999; 56(Suppl 72) S-41-S-45
46 European Committee for Standardization. Haemodialysers, haemodiafilters, haemofilters, haemoconcentrators and their extracorporeal circuits. EN 1283:1996
47 Benz K, Nauck M, Beck K H, Böhler J, Fischer K G. Filtration characteristics of recombinant hirudin by different hemodialyzers in vitro (Abst). Ann Hematol . 2000; 79 A26
48 Koster A, Merkle F, Hansen R. Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: assessment of different filter systems. Anesth Analg . 2000; 91 265-269
49 Bauersachs R M, Lindhoff-Last E, Ehrly A M. Treatment of hirudin overdosage in a patient with chronic renal failure. Thromb Haemost . 1999; 81 323-324
50 Daugirdas J T, Van Stone C J. Hemodialysis: physiologic principles and urea kinetic modeling. In: Daugirdas JT, Blake PG, Ing TS, eds. Handbook of Dialysis, 3rd ed Boston, MA: Little Brown 2001: 15-45
51 Sigler M H, Teehan B P, Daugirdas J T, Ing T S. Hemodialysis: slow continuous therapies. In: Daugirdas JT, Blake PG, Ing TS, eds. Handbook of Dialysis, 3rd ed Boston, MA: Little Brown 2001: 199-230
52 Ismail N, Neyra R, Hakim R M. Plasmapheresis. In: Daugirdas JT, Blake PG, Ing TS, eds. Handbook of Dialysis, 3rd ed Boston, MA: Little Brown 2001: 231-262
53 Fischer K G, Weiner S M, Benz K, Nauck M, Böhler J. Treatment of hirudin overdose with hemofiltration (Abst). Blood Purif . 2000; 18 80-81
54 Lewis B E, Wallis D E, Berkowitz S D. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation . 2001; 103 1838-1843
55 Lewis B E, Hursting M J. Argatroban therapy in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia, 2nd ed New York: Dekker 2001: 381-407
56 Swan S K, Hursting M J. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy . 2000; 20 318-329